New and experimental HIV treatments
Janssen | 10 hours ago
Janssen-Cilag International NV (Janssen) today announced that the European Commission (EC) has approved the use of REZOLSTA ® (darunavir/cobicistat) in combination with other antiretroviral (ARV) medicinal products for the treatment of human immunodeficiency virus - 1 (HIV - 1) infection in adults aged 18 years or older. "REZOLSTA ® eliminates the need to take a boosting agent in a separate tablet with once - daily darunavir, reducing the pill burden for patients," said Christiane Moecklinghoff, M.D Ph.D, Medical Director, Virology, Janssen EMEA.
Injecting drug use
The Guardian | 12 hours ago
Handing the reins to the Department of Health might seem a liberal-minded approach, but it could mean less is spent on treatment. Drug use simply doesn’t cause as much ill-health as other risky behaviours, so isn't prioritised by health officials. But it is seen as a major cause of crime.
Testing policies and guidelines
MEDFASH press release | 13 hours ago
With a quarter of the estimated 108,000 people living with HIV i still going undiagnosed, MEDFASH has developed HIV Testing in Practice (HIV TIPs), an online educational tool, to help increase rates of HIV diagnosis in primary care. Launched in National HIV Testing Week, the interactive webtool will enable GPs, practice nurses and their teams to raise their knowledge of HIV and enhance their confidence in offering HIV testing.
The Body | 16 hours ago
Have you heard of the START (Strategic Timing of Antiretroviral Treatment) study? In my opinion, it is probably the most important study currently running. It generates strong views, both for and against initiating antiretroviral therapy early, but the results are likely to be surprising.
HIV prevention policy
The Conversation | 17 hours ago
Two years ago, the “beginning of the end” of AIDS was announced. It included the promise of reducing HIV transmission by reducing the amount of infectious virus in the population. But disease control will fail unless we understand and plan for its translation within complex and adaptive systems. People take up technologies and use them in unanticipated ways. Cultures develop resistance in the same way that bacteria do. We will only ever approach the beginning of the end of AIDS if and when we bear these things in mind.
Inter Press Service | 17 hours ago
HIV among teenagers is devastating families in Nigeria and elsewhere in Africa, where AIDS has become the leading cause of death among adolescents. One reason for this shocking teen death toll is the low number of adolescents on antiretroviral treatment (ART).
Injecting drug use
DrugScope | 17 hours ago
A response to the Secretary of State for Work and Pensions' article "Now fight the methadone industry that keeps addicts hooked".
The search for a cure
Infection Control Today | 18 hours ago
HIV-1-infected U.S. military members and beneficiaries treated with antiretroviral therapy (ART) soon after infection were half as likely to develop AIDS and were more likely to reconstitute their immune-fighting CD4+ T-cells to normal levels, researchers reported Nov. 24 in JAMA Internal Medicine.
Injecting drug use
The Economist | 24 November 2014
Last year nearly 700,000 Americans took the drug, twice as many as a decade ago. It is now more popular than crack, by some measures. What explains heroin’s return?
Epidemiology and behaviour
The Conversation | 24 November 2014
The Australian Study of Health and Relationships (ASHR), the latest findings of which were released recently, has much to commend it. Like its counterpart, the British National Survey of Sexual Attitudes and Lifestyles (NATSAL), it provides an illustration of sexual practices of today’s adults. Both studies leave out a significant proportion of the population – older adults.